237 related articles for article (PubMed ID: 25151959)
1. Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study.
Junlén HR; Peterson S; Kimby E; Lockmer S; Lindén O; Nilsson-Ehle H; Erlanson M; Hagberg H; Rådlund A; Hagberg O; Wahlin BE
Leukemia; 2015 Mar; 29(3):668-76. PubMed ID: 25151959
[TBL] [Abstract][Full Text] [Related]
2. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
3. Long-term survey of survival time, histological transformation, and secondary malignancies in Japanese patients with advanced-stage follicular lymphoma in the rituximab era: Hokkaido Hematology Study Group.
Hirayama Y; Ishitani K; Ota S; Kurosawa M; Kondo T; Takimoto R; Mori A; Sakai H; Torimoto Y; Yamamoto S; Sato K; Iwasaki H; Kohda K; Ishida T; Kakinoki Y; Fukuhara T; Kato J
Int J Hematol; 2014 Sep; 100(3):281-9. PubMed ID: 25052874
[TBL] [Abstract][Full Text] [Related]
4. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.
Link BK; Maurer MJ; Nowakowski GS; Ansell SM; Macon WR; Syrbu SI; Slager SL; Thompson CA; Inwards DJ; Johnston PB; Colgan JP; Witzig TE; Habermann TM; Cerhan JR
J Clin Oncol; 2013 Sep; 31(26):3272-8. PubMed ID: 23897955
[TBL] [Abstract][Full Text] [Related]
5. NICE guidance on rituximab for first-line treatment of symptomatic stage III-IV follicular lymphoma in previously untreated patients.
Doss S; Garrett Z; Sutcliffe F; Stevens A
Lancet Oncol; 2012 Feb; 13(2):128-30. PubMed ID: 22403811
[No Abstract] [Full Text] [Related]
6. The 3q27 and 18q21 translocations for follicular lymphoma and diffuse large B-cell lymphoma in the rituximab era.
Watanabe R; Tomita N; Matsumoto C; Hattori Y; Matsuura S; Takasaki H; Hashimoto C; Fujita H; Fujisawa S; Ishigatsubo Y
J Clin Exp Hematop; 2013; 53(2):107-14. PubMed ID: 23995106
[TBL] [Abstract][Full Text] [Related]
7. Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
Nicolas-Virelizier E; Ségura-Ferlay C; Ghesquières H; Chassagne-Clément C; Gargi T; Biron P; Belhabri A; Rey P; Faurie P; Chabaud S; Sebban C
Hematol Oncol; 2015 Mar; 33(1):1-8. PubMed ID: 24496668
[TBL] [Abstract][Full Text] [Related]
8. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
[TBL] [Abstract][Full Text] [Related]
9. Rituximab maintenance versus radioimmunotherapy consolidation in follicular lymphoma: which, when, and for whom?
Forstpointner R; Dreyling M
Curr Hematol Malig Rep; 2011 Dec; 6(4):207-15. PubMed ID: 21909660
[TBL] [Abstract][Full Text] [Related]
10. Haematological cancer: rituximab maintenance improves the outcome of elderly patients with FL.
Jones B
Nat Rev Clin Oncol; 2013 Nov; 10(11):607. PubMed ID: 23999211
[No Abstract] [Full Text] [Related]
11. Has the time to come leave the "watch-and-wait" strategy in newly diagnosed asymptomatic follicular lymphoma patients?
Rueda A; Casanova M; Redondo M; Pérez-Ruiz E; Medina-Pérez A
BMC Cancer; 2012 May; 12():210. PubMed ID: 22650448
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.
Baiocchi RA; Alinari L; Lustberg ME; Lin TS; Porcu P; Li X; Johnston JS; Byrd JC; Blum KA
Cancer; 2011 Jun; 117(11):2442-51. PubMed ID: 24048792
[TBL] [Abstract][Full Text] [Related]
13. Rituximab use and survival after diffuse large B-cell or follicular lymphoma: a population-based study.
Keegan TH; Moy LM; Foran JM; Alizadeh AA; Chang ET; Shema SJ; Schupp CW; Clarke CA; Glaser SL
Leuk Lymphoma; 2013 Apr; 54(4):743-51. PubMed ID: 22957852
[TBL] [Abstract][Full Text] [Related]
14. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.
Vidal L; Gafter-Gvili A; Salles G; Bousseta S; Oberman B; Rubin C; van Oers MH; Fortpied C; Ghielmini M; Pettengell R; Witzens-Harig M; Dreger P; Vitolo U; Gomes da Silva M; Evangelista A; Li H; Freedman L; Habermann TM; Shpilberg O
Eur J Cancer; 2017 May; 76():216-225. PubMed ID: 28336303
[TBL] [Abstract][Full Text] [Related]
15. [Cost-effectiveness analysis of maintenance therapy with rituximab in patients with follicular lymphoma responding to induction therapy at the first line].
Castro Gómez AJ; López-Guillermo A; Rueda Domínguez A; Salar A; Varela Moreno C; Rubio-Terrés C
Rev Esp Salud Publica; 2012; 86(2):163-76. PubMed ID: 22991059
[TBL] [Abstract][Full Text] [Related]
16. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience.
Tan D; Horning SJ; Hoppe RT; Levy R; Rosenberg SA; Sigal BM; Warnke RA; Natkunam Y; Han SS; Yuen A; Plevritis SK; Advani RH
Blood; 2013 Aug; 122(6):981-7. PubMed ID: 23777769
[TBL] [Abstract][Full Text] [Related]
17. Rituximab maintenance improves overall survival in follicular lymphoma: A retrospective nationwide real-world analysis from Taiwan Cancer Registry Database.
Huang HH; Wen YC; Chen HM; Hsiao FY; Ko BS
Cancer Med; 2018 Aug; 7(8):3582-3591. PubMed ID: 30009424
[TBL] [Abstract][Full Text] [Related]
18. Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States.
Nabhan C; Zhou X; Day BM; Dawson K; Zelenetz AD; Friedberg JW; Cerhan JR; Link BK; Flowers CR
Am J Hematol; 2016 Aug; 91(8):770-5. PubMed ID: 27124800
[TBL] [Abstract][Full Text] [Related]
19. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.
Alonso-Álvarez S; Magnano L; Alcoceba M; Andrade-Campos M; Espinosa-Lara N; Rodríguez G; Mercadal S; Carro I; Sancho JM; Moreno M; Salar A; García-Pallarols F; Arranz R; Cannata J; Terol MJ; Teruel AI; Rodríguez A; Jiménez-Ubieto A; González de Villambrosia S; Bello JL; López L; Monsalvo S; Novelli S; de Cabo E; Infante MS; Pardal E; García-Álvarez M; Delgado J; González M; Martín A; López-Guillermo A; Caballero MD
Br J Haematol; 2017 Sep; 178(5):699-708. PubMed ID: 28782811
[TBL] [Abstract][Full Text] [Related]
20. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]